Key result
Progressing from prehypertension to hypertension is linked to ~16% higher GI cancer risk versus reverting to normotension.
Why the study?
Hypertension is associated with gastrointestinal cancers, but the association between prehypertension and cancer risk remains uncertain.
Does progression from prehypertension to hypertension increase the risk of gastrointestinal cancer in individuals with baseline prehypertension?
Population
131,167 individuals in a Korean health-screening cohort with prehypertension
Comparison
Progression to hypertension vs persistence of prehypertension vs reversion to normotension
Design
Nationwide health-screening cohort study
Authors
Loading...
Does not support practice change for GI cancer prevention; leaves open whether progression causally elevates risk and needs prospective trials.
Cohort (n=131,167)
Yes
Does progression from prehypertension to hypertension increase the risk of gastrointestinal cancer in individuals with baseline prehypertension?
Effect estimate: aHR 1.16 (95% CI 1.08–1.26)
Absolute Event Rate: 5% vs 3.5%
p-value: p=<0.001
Progression from prehypertension to hypertension is associated with a 16% increased risk of gastrointestinal cancers, suggesting that early blood pressure management may reduce long-term oncological burden.
Yoon et al. (2026) conducted a cohort in Adults aged 40–79 years with baseline prehypertension (SBP 120–139 mmHg and/or DBP 80–89 mmHg) from a Korean nationwide health-screening cohort (n=131,167). Progression to hypertension vs. Reversion to normotension was evaluated on Incidence of gastrointestinal (GI) cancer defined by hospitalization with GI cancer ICD-10 codes (aHR 1.16, 95% CI 1.08–1.26, p=<0.001). Progression from prehypertension to hypertension was associated with a 16% increased risk of gastrointestinal cancer compared to reversion to normotension (aHR 1.16, 95% CI 1.08–1.26) over 10.7 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: